Progyny, Inc. Announces Share Repurchase Program
Rhea-AI Summary
Progyny (Nasdaq: PGNY) announced that its board approved a share repurchase program authorizing buybacks of up to $200 million of common stock. The program will be funded with available cash and may use open-market and Rule 10b5-1 plans, with timing and size depending on market conditions.
AI-generated analysis. Not financial advice.
Positive
- Board authorizes up to $200 million in share repurchases
- Buybacks funded from available cash balances, not new financing
Negative
- Company gives no assurance on number of shares repurchased
- Repurchase program may be suspended or discontinued at any time
Key Figures
Market Reality Check
Peers on Argus
PGNY was up 0.77% pre-news while peers showed mixed moves: OSCR +1.98%, MOH +0.95%, ALHC +0.65%, CLOV -1.11%, NEUE -0.69%, suggesting stock-specific dynamics rather than a sector-wide swing.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 11 | Conference appearance | Neutral | -4.9% | Announcement of participation in BofA Securities 2026 Health Care Conference. |
| May 07 | Earnings results | Positive | +23.8% | Record Q1 2026 revenue, profitability and share repurchases update. |
| Apr 23 | Earnings date set | Neutral | -1.8% | Scheduled release date and call details for Q1 2026 results. |
| Apr 16 | Product launch | Positive | +3.1% | Launch of Progyny Select fully insured supplemental fertility and health plan. |
| Apr 01 | Corporate milestone | Positive | -0.7% | 10-year anniversary highlighting membership, employer base and coverage growth. |
Earnings and product launches have coincided with positive moves, while conference and general news have often seen mild negative reactions.
Over the last two months, Progyny reported record Q1 2026 results and guidance, which coincided with a strong +23.8% move following earnings. A new fully insured supplemental plan announcement in mid-April 2026 also drew a positive reaction. In contrast, conference participation, earnings date notices, and an anniversary milestone saw modest declines between -0.7% and -4.9%. Against this backdrop, the new $200 million repurchase authorization follows completion of a prior $200 million program noted in recent filings.
Market Pulse Summary
This announcement introduced a new $200 million share repurchase program funded from existing cash, following disclosure of $225.1 million in cash and marketable securities and no debt as of Q1 2026. It comes after a prior $200 million buyback was completed, indicating ongoing capital return. Investors may focus on how quickly management executes repurchases, any changes to liquidity or credit usage, and how this interacts with recent earnings and growth initiatives.
Key Terms
open market repurchases financial
Rule 10b5-1 regulatory
AI-generated analysis. Not financial advice.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced that its Board of Directors has approved a share repurchase program to repurchase up to
Shares may be repurchased through open market repurchases, including through plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, depending on stock price, market conditions and other factors deemed relevant in the Company’s sole discretion. The program may be suspended or discontinued at any time. There can be no assurances as to how many shares the Company will repurchase, if any, or at what prices any purchases will be made.
About Progyny
Progyny (Nasdaq: PGNY) is a global leader in women’s health and family building solutions, trusted by the nation’s leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients, and physicians.
Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs.
Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.
For Further Information, Please Contact:
Investors:
James Hart
investors@progyny.com
Media:
Alexis Ford
media@progyny.com
